On 16 October iBio, Inc. (NYSEMKT:IBIO) confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch” platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to … Continue reading Big Movers: iBio, Inc. (NYSEMKT: IBIO), Delta Air Lines, Inc. (NYSE:DAL), Silicon Motion Technology Corp. (NASDAQ:SIMO), SunOpta Inc. (NASDAQ:STKL), Caesars Acquisition (NASDAQ:CACQ)